Mirum Pharmaceuticals, Inc. has disclosed a series of stock transactions involving director Saira Ramasastry. This event is noteworthy as it underscores the ongoing activity within the pharmaceutical sector, particularly in the realm of equity management.
Background
Mirum Pharmaceuticals, Inc. is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker symbol MIRM. Recent filings include a Form 4 submitted on November 17, 2026, which details the stock transactions by Ramasastry.
What the Filing Says
According to the SEC filing (accession number 0001547959-26-000019), Ramasastry reported two significant transactions on November 16, 2026. The first involved acquiring 2,000 shares of common stock at a price of $28.97 per share. The second transaction involved selling 2,000 shares at a price of $92.28 per share. The filing notes, "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on August 10, 2026." Additionally, Ramasastry exercised stock options for 2,000 shares, which are fully vested.
Impact
This update may affect shareholders and investors as it reflects the strategic decisions made by a key director within the company. The transactions highlight Ramasastry's active role in managing her equity stake in Mirum Pharmaceuticals, which can influence investor sentiment and perceptions of the company's future direction.
What's Next
The filing does not say what happens next.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




